Cover Image
市場調查報告書

拉薩熱:開發中產品分析

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363115
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
拉薩熱:開發中產品分析 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 54 Pages
簡介

本報告提供拉薩熱治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

拉薩熱概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

拉薩熱:企業開發中的治療藥

拉薩熱:大學/機關研究中的治療藥

拉薩熱:開發中產品概況

  • 初期階段的產品

拉薩熱:企業開發中的產品

拉薩熱:大學/機關研究中的產品

rassa環境熱能治療藥的開發企業

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • Profectus BioSciences, Inc.
  • SIGA Technologies, Inc.

拉薩熱:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

拉薩熱:暫停中的計劃

拉薩熱:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8837IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lassa Fever (Lassa Hemorrhagic Fever) Overview
  • Therapeutics Development
    • Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Overview
    • Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis
    • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Development by Companies
    • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Products Glance
    • Early Stage Products
  • Lassa Fever (Lassa Hemorrhagic Fever) - Products under Development by Companies
  • Lassa Fever (Lassa Hemorrhagic Fever) - Products under Investigation by Universities/Institutes
  • Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
    • Arno Therapeutics Inc
    • Celgene Corp
    • Etubics Corp
    • Kineta Inc
    • Profectus BioSciences Inc
    • SIGA Technologies Inc
  • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-11050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBH-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHF-535 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Lassa Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lassa Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
  • Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
    • Featured News & Press Releases
      • May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
      • Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
      • May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016
  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by SIGA Technologies Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016
  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top